Merrimack Pharmaceuticals announces a deal with the French drug company Ipsen and a strategic pipeli


On Sunday, Merrimack announced its plans to sell off its commercial asset ONIVYDE® and generic version of DOXIL® to Ipsen group in a deal valued around $1B. In this deal, Merrimack retains up to $33M in future milestones pursuant to its exclusive license with Shire, but will sell commercialization rights in the U.S. and its licensing agreement with Shire.

Merrimack will receive $575M at closing and up to $450M in approval-based milestone payments. These milestones include $225M upon FDA approval in front-line pancreatic cancer, $150M for approval in SCLC, and $75M for approval in any other indication.

Merrimack plans to use the cash infusion to settle its debt and fund development through 1H19. They will also return $200M to its shareholders in a dividend equal to around $1.54/share and 100% of the $450M in approval-based milestones.

If you owned shares in MACK last Friday, this deal will provide a nice return with the $1.54/share dividend.

If this deal goes through, it effectively turns Merrimack into an early-stage biotech with a favorable balance sheet. This is a large departure from a commercial stage company and buyout candidate. Since our initial thesis placed emphasis on ONIVYDE® as the major value driver going forward, a re-evaluation of MM-121, MM-141, and MM-310 is prudent before making an investment.

Institutions own >65%, so it remains to be seen whether this deal gets approved or not.

Merrimack Pharmaceuticals (MACK) is one of Amp Biotech Research's quarterly picks for Q1 2017. Amp is a biotech research firm that publishes a quarterly list of companies with attractive valuations and near-term catalysts. To see all of Amp's picks for Q1 2017, go to www.ampbioresearch.com.

Find the press release here: http://investors.merrimackpharma.com/releasedetail.cfm?ReleaseID=1006997


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon